Anti‐tumor activity of PI3K and mTOR inhibitors has been shown in human PTCL cell lines and mouse models with constitutive PI3K/AKT pathway activation (Cortes et al, 2018; Horwitz et al, 2018; Ng et al, 2018). This evidence concerns the gene AKT1 and mature T-cell and NK-cell non-Hodgkin lymphoma.